Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Patents
US court allows Teva to resume US sales of its generic version of Lotrel
June 26th, 2007
Novartis will immediately launch its own generic version of Lotrel(R) in the United States through its Sandoz division after a federal court judge today declined a request from Novartis to stop Teva Pharmaceuticals from resuming shipments of generic copies of the hypertension drug. Novartis will continue pursuing its defense of intellectual property rights for Lotrel since its US patent is still valid until 2017. Today's court's decision allows Teva to resume shipping generic copies of Lotrel. A trial date has not been set for the ongoing patent infringement lawsuit against Teva in a New Jersey federal court. Teva, which began selling a generic...
Source: Drug Law Weekly (2007-06-26)
|
